ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,284.91
0.20%
Dow Jones
42,167.05
0.60%
Gold vs US Dollar
2,671.405
0.53%
Brent Oil
71.025
-2.96%
Bitcoin
65,189.85
3.26%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ABVC BioPharma Inc (ABVC)

  7. ABVC BioPharma Inc (ABVC) News

ABVC BioPharma (ABVC)

ABVC BioPharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABVC
DateTimeSourceHeadlineSymbolCompany
10/09/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
20/08/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
16/08/202421:31Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
16/08/202421:30Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
16/08/202421:30Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
15/08/202412:30GlobeNewswire Inc.ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsNASDAQ:ABVCABVC BioPharma Inc
15/08/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
14/08/202420:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABVCABVC BioPharma Inc
07/08/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ABVCABVC BioPharma Inc
02/08/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ABVCABVC BioPharma Inc
26/07/202421:30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ABVCABVC BioPharma Inc
23/07/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
12/07/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
12/07/202421:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
24/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
23/05/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
23/05/202421:30Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
22/05/202422:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
22/05/202419:31Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
17/05/202422:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
17/05/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABVCABVC BioPharma Inc
15/05/202422:00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ABVCABVC BioPharma Inc
15/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
09/05/202414:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
18/04/202414:25GlobeNewswire Inc.AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareNASDAQ:ABVCABVC BioPharma Inc
17/04/202414:00GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MNASDAQ:ABVCABVC BioPharma Inc
10/04/202413:30GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MNASDAQ:ABVCABVC BioPharma Inc
26/03/202412:30GlobeNewswire Inc.ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MNASDAQ:ABVCABVC BioPharma Inc
21/03/202412:30GlobeNewswire Inc.AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsNASDAQ:ABVCABVC BioPharma Inc
19/03/202412:30GlobeNewswire Inc.ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineNASDAQ:ABVCABVC BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:ABVC

Your Recent History

LSE
SYME
Supply@me Capital
LSE
AGL
Angle
LSE
ENET
Ethernity Networks
LSE
VAST
Vast Resources
LSE
GGP
Greatland Gold
LSE
PXC
Phoenix Copper
LSE
AAZ
Anglo Asian Mining
LSE
PANR
Pantheon Resources
LSE
GEX
Georgina Energy
LSE
SOLG
Solgold
LSE
BP.
Bp
LSE
POS
Plexus
LSE
GKP
Gulf Keystone Petroleum
LSE
GPM
Golden Prospect Precious...
LSE
BIRD
Blackbird
LSE
HE1
Helium One Global
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved